Tecnemab K1 (anti-melanoma mab fragments)
- Region
- 🇪🇺 EU
- Active substance
- anti-melanoma mab fragments
- Company
- Amersham Sorin S.r.l.
- Status
- Withdrawn
- Therapeutic area
- Radioimmunodetection
- EU approval
- Thu 05 Sep 1996
- Application
- EMEA/H/C/000068
- ATC
- V09IA02
- Official record
- www.ema.europa.eu
Indication
As an adjunct to other diagnostic procedures for visualization by radioimmunoscintigraphy (RIS) of regional lymph node and distant metastases in the staging and follow-up of patients with stage I-III melanoma. Aid in differential diagnosis of suspected ocular melanoma.
Regulatory milestones
No milestones recorded in the last year.
Follow Tecnemab K1
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.